Merck & Co Inc (MRK)

65.54
0.38 0.58
NYSE : Health Care
Prev Close 65.92
Open 66.12
Day Low/High 65.54 / 66.27
52 Wk Low/High 55.10 / 66.80
Volume 8.10M
Avg Volume 9.00M
Exchange NYSE
Shares Outstanding 2.74B
Market Cap 180.96B
EPS 1.40
P/E Ratio 42.14
Div & Yield 1.88 (2.80%)

Latest News

Senate Punts Vote on Healthcare Bill, Wall Street Fares Poorly

Senate Punts Vote on Healthcare Bill, Wall Street Fares Poorly

Healthcare's slide weighs on rest of markets.

11 Victims of the Latest Surprising Global Cyberattack

11 Victims of the Latest Surprising Global Cyberattack

The attacks freeze IT systems and demand $300 cryptocurrency to unlock trapped files.

Merck Says It's a Victim of Global Hack

Merck Says It's a Victim of Global Hack

Merck tweeted about the hack.

Does Merck's Rally Have Legs?

Does Merck's Rally Have Legs?

MRK has shaped up on the charts.

Income Seeker: 15 Dividend Stocks for This Summer

Chris Ciaccia takes a look at 15 solid companies with good international exposure that are likely to hold up if it turns out to be a long, hot summer for stocks.

Merck Provides Update On REVEAL Outcomes Study Of Anacetrapib

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid modification) outcomes study of anacetrapib met its...

Could Merck and Leap Union Be the One for Keytruda?

Could Merck and Leap Union Be the One for Keytruda?

The Merck collab would count as Leap's first of planned studies with immunotherapies, but the collaboration is not Keytruda's first rodeo.

On Not Talking About the 'Market'; Darth Vader, Meet Amazon: Jim Cramer's Best Blog

On Not Talking About the 'Market'; Darth Vader, Meet Amazon: Jim Cramer's Best Blog

Jim Cramer discusses not discussing the 'market' and also suggests a Darth Vader-Amazon meeting.

Cramer: Stop Talking About the 'Market'

Cramer: Stop Talking About the 'Market'

It just isn't as useful or descriptive right now.

Merck's Powerful Rally Is Coming So Back Up the Truck

Merck's Powerful Rally Is Coming So Back Up the Truck

Merck is extending this week's impressive rally and will soon retest the 2017 highs.

Merck And Premier Inc. Expand Collaboration To Address Chronic Care And Vaccination Rates

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Premier Inc.

Dems Roast Trump for Leaving Medicare Out of Drug Price Order

Dems Roast Trump for Leaving Medicare Out of Drug Price Order

The main thrust of the order appears to be easing regulatory hurdles to drug approvals, which could lower the cost of bringing new treatments to market and thus lower prices.

Why Alexion's Gain In the C-Suite Doesn't Bode Well For Biogen Takeout Prospects

Why Alexion's Gain In the C-Suite Doesn't Bode Well For Biogen Takeout Prospects

Paul Clancy's move to another biotech firm could mean that there's nothing imminent in terms of Biogen being bought out, says Mizuho analyst Salim Syed.

Merck Shares Trade Down After 2 Late-Stage Trials Suspended

Merck Shares Trade Down After 2 Late-Stage Trials Suspended

The company is hitting pause on immunotherapy trials for its Keytruda drug to investigate more reports of deaths in trial groups.

Merck Provides Update On Multiple Myeloma Studies KEYNOTE-183 And 185 Of KEYTRUDA® (pembrolizumab) In Combination With Other Therapies

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on two combination studies of KEYTRUDA ® (pembrolizumab), the company's anti-PD-1 therapy, in the blood cancer multiple...

Merck And Pfizer Announce That Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint In Two Phase 3 Studies

Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc.

Initiating Position in Biotech; Update on ACRX

We're buying a small position in Inovio Pharmaceuticals and downgrading AcelRx.

Moving on From Merck

We were playing with the house's money on this one.

4 Undervalued Biotech Stocks

4 Undervalued Biotech Stocks

Two are turnaround stories, and two are oversold.

Updated Data From KEYNOTE-024 Show Continued Overall Survival Benefit Of Merck's KEYTRUDA® (pembrolizumab) Compared To Chemotherapy In The First-Line Treatment Of Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With High Levels Of PD-L1

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated overall survival (OS) findings from KEYNOTE-024, the phase 3 study evaluating KEYTRUDA ® (pembrolizumab), the company's...

New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes With Combination Of Merck's KEYTRUDA® (pembrolizumab) Plus Standard Neoadjuvant Therapy In Patients With High-Risk Breast Cancer

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and QuantumLeap Healthcare Collaborative, today announced results from the Phase 2 I-SPY 2 TRIAL investigating KEYTRUDA ® (pembrolizumab), Merck's...

Updated Data From ECHO-202 Trial Of Incyte's Epacadostat In Combination With Merck's KEYTRUDA® (Pembrolizumab) Demonstrate Clinical Activity Across Multiple Tumor Types

Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated data from the ongoing Phase 1/2 ECHO-202 trial evaluating epacadostat, Incyte's...

Missing Patients Cloud View of Incyte's IDO Drug Lung Cancer Study

Missing Patients Cloud View of Incyte's IDO Drug Lung Cancer Study

Incyte's actions are another reminder that biotech companies carefully groom and manage the clinical data they want investors to see, even at important, open medical meetings like ASCO.

New Monotherapy Data For Merck's KEYTRUDA® (pembrolizumab) In Heavily Pre-Treated Patients With Advanced Gastric Cancer To Be Presented At 2017 ASCO Annual Meeting

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from Cohort 1 of the phase 2 registrational KEYNOTE-059 trial investigating KEYTRUDA ® (pembrolizumab), the company's...

With More Than One-Year Follow-Up, Merck's KEYTRUDA® (pembrolizumab) Shows Continued Overall Survival Benefit Over Chemotherapy As Second-Line Treatment For Advanced Urothelial Carcinoma Patients Post-Platinum Failure

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated results from KEYNOTE-045 and KEYNOTE-052, two studies investigating KEYTRUDA ® (pembrolizumab), the company's anti-PD-1...

Combination Of Incyte's Epacadostat Plus Merck's KEYTRUDA® (pembrolizumab) Demonstrates Activity In Clinical Trial Of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated data from the advanced non-small cell lung cancer (NSCLC) patient cohort of the ongoing Phase...